Advanced

The cost-effectiveness of infliximab (Remicade((R))) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.

Kobelt, G; Jönsson, L; Young, A and Eberhardt, Kerstin LU (2003) In Rheumatology1999-01-01+01:00 42(2). p.326-335
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Rheumatology1999-01-01+01:00
volume
42
issue
2
pages
326 - 335
publisher
Oxford University Press
external identifiers
  • pmid:12595631
  • wos:000181378100021
  • scopus:0345294739
ISSN
1462-0332
DOI
10.1093/rheumatology/keg107
language
English
LU publication?
yes
id
8b8b9db8-e095-4143-bef3-ec64b52810f3 (old id 112262)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12595631&dopt=Abstract
date added to LUP
2007-07-04 13:32:24
date last changed
2018-01-07 09:00:23
@article{8b8b9db8-e095-4143-bef3-ec64b52810f3,
  author       = {Kobelt, G and Jönsson, L and Young, A and Eberhardt, Kerstin},
  issn         = {1462-0332},
  language     = {eng},
  number       = {2},
  pages        = {326--335},
  publisher    = {Oxford University Press},
  series       = {Rheumatology1999-01-01+01:00},
  title        = {The cost-effectiveness of infliximab (Remicade((R))) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.},
  url          = {http://dx.doi.org/10.1093/rheumatology/keg107},
  volume       = {42},
  year         = {2003},
}